National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 19779-19780 [2011-8435]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 68 / Friday, April 8, 2011 / Notices
disabilities, illnesses, conditions, and
deaths (and their associated time
frames) associated with each category of
vaccines included on the Table. See
sections 2114(c) and 2114(e)(2) of the
PHS Act, 42 U.S.C. 300aa–14(c) and
30aa–14(e)(2). Finally, section
2114(c)(2) of the PHS Act, 42 U.S.C.
300aa–14(c)(2) provides that:
srobinson on DSKHWCL6B1PROD with NOTICES
[a]ny person (including the Advisory
Commission on Childhood Vaccines) may
petition the Secretary to propose regulations
to amend the Vaccine Injury Table. Unless
clearly frivolous, or initiated by the
Commission, any such petition shall be
referred to the Commission for its
recommendations. Following—
(A) receipt of any recommendation of the
Commission, or
(B) 180 days after the date of the referral
to the Commission, whichever occurs first,
the Secretary shall conduct a rule-making
proceeding on the matters proposed in the
petition or publish in the Federal Register a
statement of reasons for not conducting such
proceeding.
On September 9, 2010, a private person
submitted a petition to amend the Table.
This petition was submitted to the Chief
Special Master, Sandra Lord, with a
copy to Dr. Geoffrey Evans, Director,
Division of Vaccine Injury
Compensation. Pursuant to the VICP
statute, Dr. Evans referred the petition to
the Commission on October 28, 2010.
The Commission discussed the petition
at its meeting on March 3, 2011. At the
conclusion of this discussion, the
Commission voted unanimously to
recommend that the Secretary not
proceed with rule-making to amend the
Table as requested in the petition.
The petition requests that the
Secretary amend the Table to include
´
Guillain-Barre Syndrome (GBS) as an
injury following certain vaccines. The
petition asserts that ‘‘[e]very drug
company admits that GBS is linked to
many different vaccines including
influenza, meningitis, and cervical
cancer [human papillomavirus].’’ The
petitioner asserts that her mother
received the seasonal influenza vaccine,
and was subsequently diagnosed with
GBS. Other than the assertion cited, the
petition does not cite scientific support,
nor indicate specifically for which
vaccines GBS should be added as an
injury, nor indicate any appropriate
time-frame.
Nonetheless, the Secretary takes very
seriously proposals to modify the Table.
Prior to receipt of the petition, in 2008,
the Secretary contracted with the
Institute of Medicine (IOM) to review
the epidemiological, clinical, and
biological evidence regarding adverse
health events associated with specific
vaccines covered by the VICP. The
vaccines to be reviewed are:
VerDate Mar<15>2010
16:41 Apr 07, 2011
Jkt 223001
• Varicella vaccines,
• influenza vaccines,
• hepatitis B vaccine,
• human papillomavirus vaccines,
• hepatitis A vaccines,
• meningococcal vaccines,
• measles-mumps rubella vaccines,
and
• diphtheria, tetanus, pertussis
vaccines.
The IOM committee will author a
consensus report with conclusions on
the evidence bearing on causality and
the evidence regarding the biological
mechanisms that underlie specific
theories for how a specific vaccine is
related to a specific adverse event. In
particular, the report will contain
updated findings on the possible causal
relationship between certain VICPcovered vaccines and GBS, as well as
other possible injuries/medical
conditions. The Secretary expects to
receive the IOM consensus report in
early summer. After receipt of the
consensus report, and a careful analysis
of the important scientific and policy
considerations raised by the findings in
the report, the Secretary will consider
whether to engage in a rule-making
proceeding to modify the Table. As
required by law, any such rule-making
proceeding would include notice and
opportunity for a public hearing and at
least 180 days of public comment. See
section 2114(c)(1) of the PHS Act, 42
U.S.C. 300aa–14(c)(1). Also as required
by law, the Secretary would provide to
the Commission a copy of the proposed
regulation or revision, request
recommendations and comments by the
Commission, and afford the
Commission at least 90 days to make
such recommendations. See section
2114(d) of the PHS Act, 42 U.S.C.
300aa–14(d).
The Secretary intends to consider
whether to engage in a rule-making
process with the benefit of the
important scientific information soon to
be provided by the IOM; to begin the
lengthy process without such additional
information would not result in rulemaking founded on the best and most
recent scientific knowledge. For these
reasons, it has been determined not to
conduct a rule-making proceeding based
on the petition received at this time.
Dated: April 1, 2011.
Mary K. Wakefield,
Administrator.
[FR Doc. 2011–8395 Filed 4–7–11; 8:45 am]
BILLING CODE 4165–15–P
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
19779
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director; Notice of Charter
Renewal
In accordance with Title 41 of the
U.S. Code of Federal Regulations,
Section 102–3.65(a), notice is hereby
given that the Charter for the Center for
Scientific Review Advisory Council
(CSRAC), formerly National Institutes of
Health Peer Review Committee, was
renewed for an additional two-year
period on March 31, 2011.
It is determined that the CSRAC is in
the public interest in connection with
the performance of duties imposed on
the National Institutes of Health by law,
and that these duties can best be
performed through the advice and
counsel of this group.
Inquiries may be directed to Jennifer
Spaeth, Director, Office of Federal
Advisory Committee Policy, Office of
the Director, National Institutes of
Health, 6701 Democracy Boulevard,
Suite 1000, Bethesda, Maryland 20892
(Mail code 4875), Telephone (301) 496–
2123, or spaethj@od.nih.gov.
Dated: April 4, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–8440 Filed 4–7–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
E:\FR\FM\08APN1.SGM
08APN1
19780
Federal Register / Vol. 76, No. 68 / Friday, April 8, 2011 / Notices
Special Emphasis Panel; NIDDK Genetics
Repository Contract Technical Application
Review.
Date: May 4, 2011.
Time: 9 a.m. to 12 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call.)
Contact Person: Xiaodu Guo, MD, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 761, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4719,
guox@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: April 4, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–8435 Filed 4–7–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
srobinson on DSKHWCL6B1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Translational
Research.
Date: May 17, 2011.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Michele L. Barnard, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 753, 6707 Democracy Boulevard,
VerDate Mar<15>2010
16:41 Apr 07, 2011
Jkt 223001
Bethesda, MD 20892–2542. (301) 594–8898.
barnardm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: April 4, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–8436 Filed 4–7–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Program
Project: Computational Cellular Imaging.
Date: May 2–3, 2011.
Time: 10 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting.)
Contact Person: Behrouz Shabestari, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5106,
MSC 7854, Bethesda, MD 20892, (301) 435–
2409, shabestb@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 4, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–8442 Filed 4–7–11; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Inherited
Disease Research Access Committee.
Date: April 29, 2011.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crowne Plaza Hotel, 8777 Georgia
Avenue, Silver Spring, MD 20910.
Contact Person: Camilla E. Day, PhD,
Scientific Review Officer, CIDR, National
Human Genome Research Institute, National
Institutes of Health, 5635 Fishers Lane, Suite
4075, Bethesda, MD 20892, 301–402–8837,
camilla.day@nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: April 4, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–8437 Filed 4–7–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5477–N–14]
Federal Property Suitable as Facilities
To Assist the Homeless
Office of the Assistant
Secretary for Community Planning and
Development, HUD.
ACTION: Notice.
AGENCY:
This Notice identifies
unutilized, underutilized, excess, and
surplus Federal property reviewed by
HUD for suitability for possible use to
assist the homeless.
FOR FURTHER INFORMATION CONTACT:
Juanita Perry, Department of Housing
and Urban Development, 451 Seventh
SUMMARY:
E:\FR\FM\08APN1.SGM
08APN1
]]>Agencies
[Federal Register Volume 76, Number 68 (Friday, April 8, 2011)]
[Notices]
[Pages 19779-19780]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-8435]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases
[[Page 19780]]
Special Emphasis Panel; NIDDK Genetics Repository Contract Technical
Application Review.
Date: May 4, 2011.
Time: 9 a.m. to 12 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892. (Telephone Conference
Call.)
Contact Person: Xiaodu Guo, MD, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 761,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-4719,
guox@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: April 4, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-8435 Filed 4-7-11; 8:45 am]
BILLING CODE 4140-01-P
